Table 1.
Patients characteristics at the time of switch from a PI- to an INI-containing regimen
| Patients characteristics | Total n=312 | RAL n=135 (43.3%) | DTG n=122 (39.1%) | EVG n=55 (17.6%) | p-value* |
|---|---|---|---|---|---|
| Female, n (%) | 85 (27.2) | 41 (30.4) | 30 (24.6) | 14 (25.5) | 0.552 |
| Age (yrs), median (IQR) | 49.3 (42.3–54.5) | 49.6 (42.8–54.0) | 50.0 (43.5–56.0) | 45.9 (40.4–53.7) | 0.146 |
| Risk group, n (%) | <0.0001 | ||||
| Heterosex | 125 (40.1) | 48 (35.6) | 49 (40.2) | 28 (50.9) | |
| MSM | 102 (32.7) | 32 (23.7) | 46 (37.7) | 24 (43.6) | |
| IVDUs | 75 (24.0) | 50 (37.0) | 22 (18.0) | 3 (5.4) | |
| Other | 10 (3.2) | 5 (3.7) | 5 (4.1) | 0 (0.0) | |
| Previous AIDS, n (%) | 86 (27.5) | 44 (32.6) | 30 (24.6) | 12 (21.8) | 0.206 |
| Previous VF, n (%) | 79 (25.3) | 46 (34.1) | 22 (18.0) | 11 (20.0) | 0.008 |
| Number of previous cART regimens, median (IQR) | 4 (2–9) | 6 (2–11) | 4 (2–7) | 3 (1–6) | 0.002 |
| Previous therapy duration (yrs), median (IQR) | 9.9 (3.9–16.7) | 11.6 (3.9–15.9) | 9.6 (5.2–17.3) | 6.8 (1.8–16.0) | 0.188 |
| CD4+ nadir (cells/mmc), median (IQR) | 179 (47–303) | 164 (40–262) | 188 (58–325) | 240 (104–333) | 0.017 |
| CD4+ nadir (cells/mmc) <200, n (%) | 163 (53.8) | 79 (58.5) | 65 (53.3) | 24 (43.6) | 0.173 |
| CD4+ (cells/mmc), median (IQR) | 599 (359–829) | 475 (286–732) | 735 (487–985) | 633 (389–837) | <0.0001 |
| CD4+ (cells/mmc) >500, n (%) | 184 (59.0) | 62 (45.9) | 88 (72.1) | 34 (61.8) | <0.001 |
| HIV-RNA >50 cp/mL, n (%) | 58 (18.6) | 34 (25.2) | 13 (10.7) | 11 (20.0) | 0.011 |
| Triglycerides (mg/dL), median (IQR) | 154 (106–243) | 155 (103–242) | 147 (104–214) | 128 (89–194) | 0.152 |
| Total Cholesterol (mg/dL), median (IQR) | 186 (157–223) | 183 (155–221) | 202 (173–234) | 188 (170–210) | 0.010 |
| HDL Cholesterol (mg/dL), median (IQR) | 41 (34–50) | 42 (35–55) | 43 (36–51) | 39 (33–47) | 0.335 |
| LDL Cholesterol (mg/dL), median (IQR) | 115 (94–134) | 103 (80–130) | 116 (95–143) | 107 (93–138) | 0.016 |
| Backbone, n (%) | <0.0001 | ||||
| TDF/FTC or TAF/FTC | 144 (46.1) | 66 (48.9) | 23 (18.8) | 55 (100.0) | |
| ABC/3TC | 120 (38.5) | 35 (25.9) | 85 (69.7) | 0 (0.0) | |
| Other | 48 (15.4) | 34 (25.2) | 14 (11.5) | 0 (0.0) | |
| STR, n (%) | 123 (39.4) | 0 (0.0) | 68 (55.7) | 55 (100.0) | <0.0001 |
| Dual regimens, n (%) | 24 (7.7) | 10 (7.4) | 14 (11.5) | 0 (0.0) | 0.016 |
| Previous PI, n (%) | <0.0001 | ||||
| ATV | 87 (27.9) | 32 (23.9) | 39 (32.0) | 16 (29.1) | |
| ATVub | 57 (18.3) | 24 (17.8) | 23 (18.8) | 10 (18.2) | |
| DRV | 72 (23.1) | 17 (12.6) | 34 (27.9) | 21 (38.2) | |
| LPV | 60 (19.2) | 43 (31.8) | 12 (9.8) | 5 (9.1) | |
| fAPV | 36 (11.5) | 19 (14.1) | 14 (11.5) | 3 (5.5) | |
| Concomitant TDF interruption, n (%) | 46 (14.7) | 10 (7.4) | 26 (21.3) | 10 (18.2) | 0.005 |
| HCV, n (%) | 97 (31.1) | 57 (42.2) | 31 (25.4) | 9 (16.4) | <0.001 |
| HBV, n (%) | 23 (7.4) | 10 (7.4) | 8 (6.6) | 5 (9.1) | 0.776 |
| Patients on statins, n (%) | 68 (21.8) | 29 (21.5) | 25 (20.5) | 14 (25.5) | 0.755 |
Note: *p-values are for χ2 or Fisher’s exact test and Kruskal-Wallis test.
Abbreviations: RAL, raltegravir; DTG, dolutegravir; EVG, elvitegravir; IQR, inter quartile range; yrs, years; n, number; MSM, men who have sex with men; IVDU, intra venous drug users; cART, combined antiretroviral therapy; cp, copies; eGFR, estimate glomerular filtration rate; STR, single tablet regimens; PI, protease inhibitor; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide.